MODERN METHODS OF MIGRAINE TREATMENT AND PREVENTION: THE USE OF MONOCLONAL ANTIBODIES AND HEPARINS.

Autor: Штробля, М. В., Штробля, А. Л., Бєлiк, Г. В., Щокіна, К. Г., Ткачова, О. В., Рижук, А. M., Матвійчук, А. В.
Předmět:
Zdroj: Likarska Sprava; 2024, Issue 3, p13-22, 10p
Abstrakt: Migraine is a globally widespread disease that significantly affects the quality of life of patients, especially women, who suffer from it much more often than men. According to the 2020 Global Burden of Disease Study, migraine is the second leading cause of disability in the world, affecting 18% of women and 6% of men. The understanding of the pathophysiology of migraine has evolved significantly, allowing us to move from perceiving this disease as just a vascular headache to considering it as a complex disorder of the nervous system. New research has identified genetic and neuropeptide mechanisms, which has contributed to the development of innovative therapeutic approaches. Due to the high prevalence and severe consequences for patients, the study of modern methods of treating migraine remains an important area of research in neurology. The aim of the study. To study modern approaches to migraine treatment, in particular acute and preventive treatment, with a focus on the latest drugs targeting the CGRP peptide. Results. Treatment of migraine is divided into acute and preventive. Acute treatment includes the use of NSAIDs, triptans, and other adjuvants. Preventive treatment includes betablockers, antiepileptic drugs, and antidepressants. Recent developments in the treatment of migraine include heparins and monoclonal antibodies, which significantly increase the effectiveness of treatment by blocking the CGRP receptor. Conclusions. Progress in understanding the mechanisms of migraine has contributed to the development of more effective drugs that target specific targets, such as the CGRP peptide. This opens up new opportunities to improve the quality of life of migraine patients by reducing the frequency of attacks and the intensity of symptoms. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index